HomER2: A Protein Involved in Cell Proliferation and Cancer Development

Target Name: HOMER2

NCBI ID: G9455

HomER2: A Protein Involved in Cell Proliferation and Cancer Development

HomER2 (CPD) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the main functions of HomER2 is to regulate the G1/S transition, which is the process by which cells move from the G1 phase (prophase) to the S phase (interphase). The G1/S transition is a critical event in the cell cycle and is closely monitored by HomER2.

In cancer, the G1/S transition is often disrupted, leading to increased cell proliferation and the development of cancer. HomER2 has been shown to play a positive role in regulating the G1/S transition in cancer cells and has been identified as a potential drug target.

One of the key benefits of targeting HomER2 is its potential to inhibit the activity of oncogenic signaling pathways. For example, HomER2 has been shown to promote the formation of cancer-associated extracellular vesicles (EVs), which are self-assembling structures that are capable of carrying out a variety of cellular processes, including drug delivery and signaling. By inhibiting the activity of oncogenic signaling pathways, HomER2 has the potential to disrupt the formation of EVs and reduce cancer cell proliferation.

Another potential mechanism by which HomER2 may contribute to cancer development is its role in the regulation of cell adhesion. HomER2 has been shown to play a positive role in the formation of tight junctions, which are specialized barriers that mediate the movement of ions and molecules across the intercellular membrane. The regulation of tight junctions is critical for maintaining the integrity of the intercellular barrier and is a critical event in the development and progression of cancer.

In addition to its role in cancer development, HomER2 is also a potential biomarker for the disease. The regulation of the G1/S transition is a critical event in the cell cycle and is often disrupted in cancer cells. By targeting HomER2, researchers may be able to develop new diagnostic tests or therapeutic strategies for the treatment of cancer.

Targeting HomER2 may also have potential therapeutic applications in other areas of medicine. For example, HomER2 has been shown to play a positive role in the regulation of ion channels, which are critical for the proper functioning of many cellular processes, including muscle contractions and nerve function. By targeting HomER2, researchers may be able to develop new treatments for a variety of neurological and cardiovascular disorders.

In conclusion, HomER2 is a protein that has important roles in regulating cell proliferation and adhesion. Its regulation of the G1/S transition has been implicated in the development and progression of cancer, and it has potential as a drug target or biomarker for the disease . Further research is needed to fully understand the role of HomER2 in disease and to develop new therapeutic strategies for the treatment of cancer and other disorders.

Protein Name: Homer Scaffold Protein 2

Functions: Postsynaptic density scaffolding protein. Binds and cross-links cytoplasmic regions of GRM1, GRM5, ITPR1, DNM3, RYR1, RYR2, SHANK1 and SHANK3. By physically linking GRM1 and GRM5 with ER-associated ITPR1 receptors, it aids the coupling of surface receptors to intracellular calcium release. May also couple GRM1 to PI3 kinase through its interaction with AGAP2. Isoforms can be differently regulated and may play an important role in maintaining the plasticity at glutamatergic synapses (PubMed:9808459). Required for normal hearing (PubMed:25816005). Negatively regulates T cell activation by inhibiting the calcineurin-NFAT pathway. Acts by competing with calcineurin/PPP3CA for NFAT protein binding, hence preventing NFAT activation by PPP3CA (PubMed:18218901)

More Common Targets